International Living Donor Liver Transplant Registry |

English Arabic China German Japanese Korea Pakistani Portuguese Russian Spanish Turkish French

Click on the relevant icon above to download the short version of the protocol in different languages.

Background: Living donor liver transplantation (LDLT) was introduced in the early 90’s to overcome an increasing shortage of available diseased donor organs for transplantation. LDLT remains the main source of grafts for liver transplantation in Asian countries, however, reports on donor morbidity and even mortality have hampered the uptake of the procedure in Western countries. Outcome data are available from developed countries, but outcomes in developing countries remain unknown. There is a need to collect data from all parts of the world, to create a single prospective registry and allow meaningful comparisons, as well as standardization of the procedure, across the globe.

Center eligibility: Any center worldwide involved in LDLT is eligible to participate in this registry. There are no minimum number of cases to be submitted or selection criteria for centers.

Team members: Each center may form a team of 3 members in total. Participants may include surgeons, anesthesiologists, hepatologists, critical care physicians and other members involved in LDLT. Auditors (data monitors) will be assigned to monitor the adherence to the registry protocol as well as auditing the quality of data collection of the participating centers.

Inclusion criteria: Cases must be prospectively registered. Both donors and recipients will be included in the registry, including adult and pediatric, two stage LDLT (e.g. APOLT, RAPID, ASPIRE, RAVAS), as well as dual grafts.

Exclusion criteria: Domino grafts will be excluded.

Outcomes: Morbidity and mortality for both the donor and recipient until hospital discharge and up to 90 days postoperatively. Additional outcome data will be captured at 12 months follow up.

Data ownership: will act as the custodian of the data. All participants will be able to access their own submitted data without the need for permission from the Committees. The Chief Investigators, Scientific and Management committees together will decide about data sharing requests and will consider all such requests based on the quality and validity of the proposed project.

Data confidentiality: There will be no surgeon, or center related data reporting, all data will be fully anonymized.

Authorship: All members, with submitted verified cases to the registry, will be PubMed cited as group authors in the main publications. Spin-off studies may include formal named authorship but must include the “ Collaborative” with group authorship for all participants.


Full protocolClick on the icon below to access the complete version of the protocol.   

CRF PDF Download


Next steps:


Lancet Gastroenterology and Hepatology Correspondence
Click here to access the Launch of article.